ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Due to the variation of the five available TKIs in terms of their potency, activity against kinases other than BCR-ABL1, as well as activity against ABL1 mutations, pharmacokinetics, and adverse effect profiles, the armamentarium to treat and monitor patients with CML has allowed for a better personalization of the therapy.